TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00848692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Two infusions of saline (NaCl 0,9 %) given two weeks apart
Study: NCT03238144

Intervention type: OTHER
Group type: OTHER
Intervention: MRF scan
Description: MRF with or without dynamic contrast-enhanced MRI scans.
Study: NCT01142219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol was administered orally at a dose of 01 g/kg/day for six months.
Study: NCT02796924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim Rapid2 Transcranial Magnetic Simulation
Description: A non-invasive method of brain stimulation
Study: NCT01967420

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social cognition training
Description: The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
Study: NCT03994926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye
Description: Device measures smooth eye pursuit and response to light flash after pt smokes cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis cigarette - 4.0% THC
Description: smoked cannabis 4.0% THC
Study: NCT00260689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study: NCT02666027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid Intravenous Alert (FIVA) 'on'
Description: Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
Study: NCT01989637

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry Meal
Description: High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Meal
Description: High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
Study: NCT01313182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mupirocin calcium ointment, 2%
Description: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.
Study: NCT02666027

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluid Intravenous Alert (FIVA) 'off'
Description: The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
Study: NCT02834312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Study: NCT02479477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio therapy
Description: during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
Study: NCT00793234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: TB-402 administered as single bolus 18-24 post total knee replacement surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: TB-402 administered as single bolus 18-24 post total knee replacement surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: TB-402 administered as single bolus 18-24 post total knee replacement surgery.
Study: NCT01313182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3M Skin and Nasal Antiseptic
Description: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
Study: NCT03275896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Transplantation
Description: The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
Study: NCT00793234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
Study: NCT01618513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin® LAR
Description: Intramuscular injections, dosage based on either GH or IGF-I levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin® LAR
Description: Intramuscular injections, dosage based on either GH or IGF-I levels.
Study: NCT03199885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study: NCT04428905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Participate in telehealth sessions
Study: NCT02072057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT02167126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity.
Study: NCT03199885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study: NCT00387205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
Study: NCT02661997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Intervention
Description: All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Intervention
Description: The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
Study: NCT02921230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral stenting
Description: stent implantation during the index procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral stenting
Description: stent implantation during the index procedure
Study: NCT03477110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A Device
Description: Undergo tumor treatment fields therapy using NovoTTF-200A device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Undergo tumor treatment fields therapy using NovoTTF-200A device
Study: NCT02943382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fingerprick autologous blood (FAB)
Description: Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
Study: NCT04470817

Intervention type: DRUG
Intervention: Azilsartan Medoxomil
Description: Azilsartan Medoxomil
Study: NCT03365856

Intervention type: OTHER
Intervention: observational study
Description: as clinical practice
Study: NCT04438915

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery
Description: The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery
Description: The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
Study: NCT03744117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care consultation
Description: A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
Study: NCT03148054

Intervention type: DEVICE
Intervention: Computer Tomography and Endoscopy
Description: Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system.
Study: NCT02397889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
Study: NCT01250951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study: NCT03001362

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy
Description: pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
Study: NCT02258295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragel
Description: Intragel has an average molecular weight of 800-1200 kDaltons.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT02167126

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping
Description: using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Tape
Description: Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape
Description: Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella.
Study: NCT00852228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV cetuximab
Description: Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV cetuximab
Description: Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI chronomodulated chemotherapy
Description: Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI conventional chemotherapy
Description: Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks.
Study: NCT01674569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops
Study: NCT02834312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Study: NCT01651052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart Valve Surgery
Description: Implant of an aortic valve, Model 11000
Study: NCT02686762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan (5 mg)
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan (50 mg)
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
Study: NCT05303948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy / Direct Laryngoscopy
Description: First pass success analysis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy / Direct Laryngoscopy
Description: First pass success analysis
Study: NCT05124496

Intervention type: DEVICE
Intervention: Screening Device
Description: Screening device comparing Rt-PCR positive and negative results to HyperDetector results
Study: NCT00374049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUC_1
Description: Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
Study: NCT01674569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
Study: NCT01894347

Intervention type: OTHER
Intervention: TDM, Monitoring of Neuro-and Nephropathology
Description: Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology